Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer

Source: 2021 Global Conference Coverage: An Update on the Clinical Development Across Gynecologic Malignancies*
The 2021 SGO Virtual Annual Meeting, 19-25 March 2021, in Seattle, Washington, USA; The 2021 ASCO Annual Meeting, 4-8 June 2021, in Chicago, Illinois, USA; The 2021 IGCS Meeting, 30 August - 2 September, in Rome, Italy; The ESMO 2021 Annual Congress, 17-21 September 2021, in Paris, France; The 2021 ESGO Conference, 23-26 October 2021, in Prague, Czech Republic

In this podcast episode, listen to Ursula Matulonis, MD, and Jubilee Brown, MD, discuss new data for gynecological cancers presented at the virtual SGO 2021 meeting, including immunotherapy-based combinations for endometrial cancer and PARP inhibitors for BRCA-mutated ovarian cancers.

This podcast is intended for clinicians practicing medicine outside of the United States.

Jubilee Brown, MD
Ursula Matulonis, MD
Released: April 7, 2021

In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including:

  • Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancer
  • Results from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA-mutated relapsed ovarian cancer
  • 5-year follow-up from SOLO-1 trial of olaparib vs placebo in BRCA-mutated, newly diagnosed ovarian cancer
  • Long-term follow-up results from the phase III ENGOT-OV16/NOVA trial of niraparib in patients with recurrent ovarian cancer
  • OPAL: a phase II study evaluating dostarlimab, bevacizumab, and niraparib in platinum-resistant ovarian cancer

Presenters:

Jubilee Brown, MD
Professor and Director of Gynecologic Oncology
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Acknowledgements

This educational activity is supported by an educational grant from
GlaxoSmithKline

Related Content

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Ursula Matulonis, MD Released: April 8, 2021

Commentaire clinique en français sur la reclassification moléculaire des cancers de l'endomètre et les principaux essais d'immunothérapie en cours, de Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: March 31, 2021

Clinical Care Options（CCO）からの、子宮内膜がんの分子的再分類と、進行中の重要な免疫療法についての臨床的コメント（中国語）

Domenica Lorusso, MD, PhD Released: March 30, 2021

Video from Clinical Care Options (CCO) of a panel of international experts reviewing the role of immunotherapy for patients with endometrial cancer.

Bradley J. Monk, MD, FACS, FACOG
Program Director person default Mansoor Raza Mirza, MD Prof Isabelle Ray Coquard Released: March 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue